Research on depression shows it is a complex condition involving interactions between brain biology, stress, genes and environment, rather than a simple “chemical imbalance.”

Brain imaging studies find altered activity and connectivity in regions involved in mood, reward and thinking, including the prefrontal cortex, hippocampus and amygdala. Neurotransmitter systems such as serotonin, noradrenaline, dopamine and GABA are disrupted in nuanced ways. Modern work also highlights glutamate signaling and synaptic plasticity as central to how depression develops and improves.

Stress is a major factor. Chronic stress activates the hypothalamic pituitary adrenal axis and raises cortisol, which can alter brain structure and function and affect immune activity. Inflammation is frequently elevated in people with depression, with higher levels of inflammatory markers and immune related changes that may influence neurotransmission and neural circuits.

Genetic studies show many common variants each contribute a small increase in risk. These genetic factors interact with life experiences, including trauma, social adversity and lifestyle, to shape vulnerability or resilience.

Treatments reflect this complexity. Traditional antidepressants, which act mainly on monoamine transmitters, often require weeks to work and are not effective for everyone. Newer approaches target synaptic plasticity and glutamate signaling, as seen with ketamine and related compounds, which can act rapidly in some patients. Psychological therapies change patterns of thought and behavior and can also produce measurable brain changes.

Overall, current research views depression as a brain network and whole body disorder shaped by stress, biology and experience, with ongoing efforts to develop more precise, personalized treatments.